Caratteristiche ed utilizzo pratico di rivaroxaban nella fibrillazione atriale e nel tromboembolismo venoso

Translated title of the contribution: Characteristics and practical use of rivaroxaban in atrial fibrillation and venous thromboembolism

Davide Imberti, Giancarlo Agnelli, Felicita Andreotti, Francesco Dentali, Gian Franco Gensini, Raffaele Landolfi, Giuseppe Micieli, Domenico Prisco

Research output: Contribution to journalArticle

Abstract

Rivaroxaban is a new oral direct factor Xa inhibitor recently approved for the treatment of venous thromboembolism (VTE) and for the prevention of stroke in nonvalvular atrial fibrillation (AF). Using a modified Delphi method, a group of Italian multidisciplinary specialists (internists, hematologists, angiologists, cardiologists, neurologists) guided by an expert panel reviewed the practical management of these clinical conditions in different healthcare settings and debated the limitations and gaps in clinical studies, national guidelines and the role of rivaroxaban in VTE and nonvalvular AF. This survey, named "EXTRA project", was divided into two arms (EXTRA-VTE, EXTRA-AF) and took place in two phases: the first was based on a questionnaire filled out on-line, and the second was a meeting attended by all the specialists to address the most controversial topics. Almost all of the participants expressed agreement in considering rivaroxaban a new cornerstone of stroke prevention and treatment of VTE. They appreciated its predictable pharmacokinetics and pharmacodynamics, the wide therapeutic window, the lack of relevant interactions with many commonly prescribed comedications, no requirement for routine coagulation monitoring or dose adjustment, and the good tolerability in a broad spectrum of patients at high risk of complications. The results are here reported and discussed together with the therapeutic contextualization and the future clinical perspectives of rivaroxaban.

Original languageItalian
JournalGiornale Italiano di Cardiologia
Volume15
Issue number6 SUPPL. 1
Publication statusPublished - 2014

Fingerprint

Venous Thromboembolism
Atrial Fibrillation
Stroke
Therapeutics
Pharmacokinetics
Guidelines
Delivery of Health Care
Rivaroxaban
Surveys and Questionnaires

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Imberti, D., Agnelli, G., Andreotti, F., Dentali, F., Gensini, G. F., Landolfi, R., ... Prisco, D. (2014). Caratteristiche ed utilizzo pratico di rivaroxaban nella fibrillazione atriale e nel tromboembolismo venoso. Giornale Italiano di Cardiologia, 15(6 SUPPL. 1).

Caratteristiche ed utilizzo pratico di rivaroxaban nella fibrillazione atriale e nel tromboembolismo venoso. / Imberti, Davide; Agnelli, Giancarlo; Andreotti, Felicita; Dentali, Francesco; Gensini, Gian Franco; Landolfi, Raffaele; Micieli, Giuseppe; Prisco, Domenico.

In: Giornale Italiano di Cardiologia, Vol. 15, No. 6 SUPPL. 1, 2014.

Research output: Contribution to journalArticle

Imberti, D, Agnelli, G, Andreotti, F, Dentali, F, Gensini, GF, Landolfi, R, Micieli, G & Prisco, D 2014, 'Caratteristiche ed utilizzo pratico di rivaroxaban nella fibrillazione atriale e nel tromboembolismo venoso', Giornale Italiano di Cardiologia, vol. 15, no. 6 SUPPL. 1.
Imberti D, Agnelli G, Andreotti F, Dentali F, Gensini GF, Landolfi R et al. Caratteristiche ed utilizzo pratico di rivaroxaban nella fibrillazione atriale e nel tromboembolismo venoso. Giornale Italiano di Cardiologia. 2014;15(6 SUPPL. 1).
Imberti, Davide ; Agnelli, Giancarlo ; Andreotti, Felicita ; Dentali, Francesco ; Gensini, Gian Franco ; Landolfi, Raffaele ; Micieli, Giuseppe ; Prisco, Domenico. / Caratteristiche ed utilizzo pratico di rivaroxaban nella fibrillazione atriale e nel tromboembolismo venoso. In: Giornale Italiano di Cardiologia. 2014 ; Vol. 15, No. 6 SUPPL. 1.
@article{993abcafae1f4f93a6f99f1de2073b97,
title = "Caratteristiche ed utilizzo pratico di rivaroxaban nella fibrillazione atriale e nel tromboembolismo venoso",
abstract = "Rivaroxaban is a new oral direct factor Xa inhibitor recently approved for the treatment of venous thromboembolism (VTE) and for the prevention of stroke in nonvalvular atrial fibrillation (AF). Using a modified Delphi method, a group of Italian multidisciplinary specialists (internists, hematologists, angiologists, cardiologists, neurologists) guided by an expert panel reviewed the practical management of these clinical conditions in different healthcare settings and debated the limitations and gaps in clinical studies, national guidelines and the role of rivaroxaban in VTE and nonvalvular AF. This survey, named {"}EXTRA project{"}, was divided into two arms (EXTRA-VTE, EXTRA-AF) and took place in two phases: the first was based on a questionnaire filled out on-line, and the second was a meeting attended by all the specialists to address the most controversial topics. Almost all of the participants expressed agreement in considering rivaroxaban a new cornerstone of stroke prevention and treatment of VTE. They appreciated its predictable pharmacokinetics and pharmacodynamics, the wide therapeutic window, the lack of relevant interactions with many commonly prescribed comedications, no requirement for routine coagulation monitoring or dose adjustment, and the good tolerability in a broad spectrum of patients at high risk of complications. The results are here reported and discussed together with the therapeutic contextualization and the future clinical perspectives of rivaroxaban.",
keywords = "Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism, Rivaroxaban, Venous thromboembolism",
author = "Davide Imberti and Giancarlo Agnelli and Felicita Andreotti and Francesco Dentali and Gensini, {Gian Franco} and Raffaele Landolfi and Giuseppe Micieli and Domenico Prisco",
year = "2014",
language = "Italian",
volume = "15",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "6 SUPPL. 1",

}

TY - JOUR

T1 - Caratteristiche ed utilizzo pratico di rivaroxaban nella fibrillazione atriale e nel tromboembolismo venoso

AU - Imberti, Davide

AU - Agnelli, Giancarlo

AU - Andreotti, Felicita

AU - Dentali, Francesco

AU - Gensini, Gian Franco

AU - Landolfi, Raffaele

AU - Micieli, Giuseppe

AU - Prisco, Domenico

PY - 2014

Y1 - 2014

N2 - Rivaroxaban is a new oral direct factor Xa inhibitor recently approved for the treatment of venous thromboembolism (VTE) and for the prevention of stroke in nonvalvular atrial fibrillation (AF). Using a modified Delphi method, a group of Italian multidisciplinary specialists (internists, hematologists, angiologists, cardiologists, neurologists) guided by an expert panel reviewed the practical management of these clinical conditions in different healthcare settings and debated the limitations and gaps in clinical studies, national guidelines and the role of rivaroxaban in VTE and nonvalvular AF. This survey, named "EXTRA project", was divided into two arms (EXTRA-VTE, EXTRA-AF) and took place in two phases: the first was based on a questionnaire filled out on-line, and the second was a meeting attended by all the specialists to address the most controversial topics. Almost all of the participants expressed agreement in considering rivaroxaban a new cornerstone of stroke prevention and treatment of VTE. They appreciated its predictable pharmacokinetics and pharmacodynamics, the wide therapeutic window, the lack of relevant interactions with many commonly prescribed comedications, no requirement for routine coagulation monitoring or dose adjustment, and the good tolerability in a broad spectrum of patients at high risk of complications. The results are here reported and discussed together with the therapeutic contextualization and the future clinical perspectives of rivaroxaban.

AB - Rivaroxaban is a new oral direct factor Xa inhibitor recently approved for the treatment of venous thromboembolism (VTE) and for the prevention of stroke in nonvalvular atrial fibrillation (AF). Using a modified Delphi method, a group of Italian multidisciplinary specialists (internists, hematologists, angiologists, cardiologists, neurologists) guided by an expert panel reviewed the practical management of these clinical conditions in different healthcare settings and debated the limitations and gaps in clinical studies, national guidelines and the role of rivaroxaban in VTE and nonvalvular AF. This survey, named "EXTRA project", was divided into two arms (EXTRA-VTE, EXTRA-AF) and took place in two phases: the first was based on a questionnaire filled out on-line, and the second was a meeting attended by all the specialists to address the most controversial topics. Almost all of the participants expressed agreement in considering rivaroxaban a new cornerstone of stroke prevention and treatment of VTE. They appreciated its predictable pharmacokinetics and pharmacodynamics, the wide therapeutic window, the lack of relevant interactions with many commonly prescribed comedications, no requirement for routine coagulation monitoring or dose adjustment, and the good tolerability in a broad spectrum of patients at high risk of complications. The results are here reported and discussed together with the therapeutic contextualization and the future clinical perspectives of rivaroxaban.

KW - Atrial fibrillation

KW - Deep vein thrombosis

KW - Pulmonary embolism

KW - Rivaroxaban

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84905867345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905867345&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:84905867345

VL - 15

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 6 SUPPL. 1

ER -